An interventional study of Extracorporeal Shockwave Therapy in Patellar Tendinopathy, sponsored by Ahmed Alshimy. Active, not recruiting at 1 site in Egypt. Open to participants aged 15 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Ahmed Alshimy · Not applicable, Interventional, and Treatment
Patellar tendinopathy (PT) is a commonly used term for the clinical manifestation of patellar tendon pain and functional limitation with multifactorial etiology. It occurs in both athletes and general population in all age groups. It is often characterized as an overuse injury resulting from chronic failure of the healing response that is not strictly linked to inflammatory or degenerative processes.
Once enrolled, participants were examined by a physiotherapist, and received the first application of ESWT (week 0). At weekly intervals, they received three more applications and on the day of the last application (week 3), a control clinical examination was performed. In the 12th-week follow-up after the last application week 15), a final examination including joint position sense, balance and kinesiophobia evaluation was performed.
285 studies on the registry are indexed under Kinesiophobia; 91 are open to participants now.
This study's enrollment of 50 is close to the median of 52 across 174 interventional studies indexed under Kinesiophobia.
Browse Kinesiophobia studies →Ahmed Alshimy is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Extracorporeal Shockwave Therapy
The low-energy focused ESWT was applied using the BTL-6000 FSWT device with piezoelectric generator and a coupling pad which modulates penetration depth to 0-35 mm. The setting was chosen based on ISMST guidelines (https://shockwavether apy.org). Energy flux density varied between 0.14 and 0.18 mJ/ mm2 due to patient tolerance, frequency was set at 8 Hz. A total of 2000 shocks were applied semi-statically to the most defined pathological area in the patellar tendon followed by2000 shocks dynamically to the quadriceps muscle.
Digital inclinometer
Time frame: 4 months
Tampa scale for Kinesiophobia
Time frame: 4 months
Biodex balance system (overall stability index)
Time frame: 4 months
Biodex balance system (Anteroposterior)
Time frame: 4 months
Biodex balance system (Mediolateral)
Time frame: 4 months
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Oct 2026, 2 months after the start.
Of 132 non-industry interventional studies with no phase under Kinesiophobia, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's planned 2 months is below that.
Counting every sponsor, half of 132 studies reached it within 8 months; a quarter within 4 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ahmed Alshimy